The federal government can be a key source of non-dilutive funding to fuel your advance to commercialization in health technology. But where to begin looking, and how to be sure you have not missed any opportunities? A comprehensive strategy is necessary, one that includes all relevant programs and players as well as granular details on which program managers to work with. Join us on June 5 to learn firsthand from Dr. Anna Kushnir and Bill McCann of SMI, a consulting firm that has helped hundreds of early-stage companies develop strategic plans to win federal funding.
Digital health is a sector of the health ecosystem that has enormous growth potential. What’s really piquing investors’ interest these days? Are there any special factors that make certain digital health companies more attractive than others? What trends are emerging, and what major unmet needs are still crying out for a solution that would bring investors running? Join us on May 1 to get answers from David Kim of the investment firm DigiTx Partners.
There is a seemingly limitless number of frameworks for strategy development. Using them well lays a critical foundation for aligning teams and investors and ensuring long term success. Kirsten Carroll will review the role strategy plays in business planning and the importance of not just developing a great one, but also communicating it effectively. She will provide examples of the frameworks that have served her particularly well in her own career with advice on when and how to use them.
Join us on Thursday, March 8, when Rosenman Institute Director Christine Winoto will interview Eric Stone, CEO and co-founder of Velano Vascular. Under Eric’s leadership, Velano’s PIVO needleless blood draw technology won FDA approval; the company raised $17 million this past March; and Velano has just been named to the 2017 Fierce 15 in Medtech.
